FibroGen Inc (NASDAQ:FGEN) has a beta value of 0.85 and has seen 2.29 million shares traded in the last trading session. The company, currently valued at $31.67M, closed the last trade at $0.31 per share which meant it lost -$0.02 on the day or -4.33% during that session. The FGEN stock price is -735.48% off its 52-week high price of $2.59 and 41.94% above the 52-week low of $0.18. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.93 million shares traded. The 3-month trading volume is 3.58 million shares.
The consensus among analysts is that FibroGen Inc (FGEN) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.02.
FibroGen Inc (NASDAQ:FGEN) trade information
Sporting -4.33% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the FGEN stock price touched $0.31 or saw a rise of 19.27%. Year-to-date, FibroGen Inc shares have moved -40.74%, while the 5-day performance has seen it change -0.38%. Over the past 30 days, the shares of FibroGen Inc (NASDAQ:FGEN) have changed -22.19%. Short interest in the company has seen 4.98 million shares shorted with days to cover at 0.61.
Wall Street analysts have a consensus price target for the stock at $28, which means that the shares’ value could jump 98.89% from current levels. The projected low price target is $28.0 while the price target rests at a high of $28.0. In that case, then, we find that the current price level is -8932.26% off the targeted high while a plunge would see the stock gain -8932.26% from current levels.
FibroGen Inc (FGEN) estimates and forecasts
The company’s shares have lost -15.87% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -52.46%.
1 analysts offering their estimates for the company have set an average revenue estimate of 2M for the current quarter. 1 have an estimated revenue figure of 2M for the next ending quarter. Year-ago sales stood 55.9M and 50.64M respectively for this quarter and the next, and analysts expect sales will shrink by -96.42% for the current quarter and -52.46% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.75% over the past 5 years. Earnings growth for 2025 is a modest -23.96% while over the next 5 years, the company’s earnings are expected to decrease by -6.51%.
FGEN Dividends
FibroGen Inc is expected to release its next earnings report on 2025-Mar-16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
Insiders own 1.03% of the company shares, while shares held by institutions stand at 36.89% with a share float percentage of 37.28%. Investors are also buoyed by the number of investors in a company, with FibroGen Inc having a total of 87.0 institutions that hold shares in the company. The top two institutional holders are PRIMECAP MANAGEMENT CO/CA/ with over 13.66 million shares worth more than $12.19 million. As of 2024-06-30, PRIMECAP MANAGEMENT CO/CA/ held 13.6785% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 8.94 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.97 million and represent 8.9508% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.47% shares in the company for having 3.5 shares of worth $1.1 million while later fund manager owns 2.92 shares of worth $0.92 million as of Dec 31, 2024 , which makes it owner of about 2.89% of company’s outstanding stock.
